Intracellular disposition of methotrexate in acute lymphoblastic leukemia in children

Current Drug Metabolism

Volumn 13, Issue 6, 2012, Pages 822-834

  De Beaumais, Tiphaine Adam ^a   Jacqz Aigrain, Evelyne ^a,b  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Acute lymphoblastic leukemia; Metabolism; Methotrexate; Pediatrics; Pharmacogenetics; Transport

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; GLYCOPROTEIN P; MERCAPTOPURINE; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; REDUCED FOLATE CARRIER;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CYTOTOXICITY; DRUG DISPOSITION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG TRANSPORT; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC TRANSFECTION; HUMAN; PHARMACOGENETICS; REVIEW; TREATMENT RESPONSE;

6-MERCAPTOPURINE; ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL TRANSPORT; CHILD; HUMANS; METHOTREXATE; POLYMORPHISM, GENETIC; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84863685052     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920012800840400     Document Type: Review

References (188)

1. Köck, K; Grube, M; Jedlitschky, G; Oevermann, L; Siegmund, W; Ritter, CA; Kroemer, HK. Expression of adenosine triphosphate-binding cassette (ABC) drug transporters in peripheral blood cells: relevance for physiology and pharmacotherapy. Clin Pharmacoki-net., 2007, 46(6), 449-470.
2. Farber, S; Diamond, LK. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N. Engl. J. Med., 1948, 238(23), 787-793.
3. Evans, WE; Crom, WR; Abromowitch, M; Dodge, R; Look, AT; Bowman, WP; George, SL; Pui, CH. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N. Engl. J. Med., 1986, 314(8), 471-477.
4. Freeman, AI; Weinberg, V; Brecher, ML; Jones, B; Glicksman, AS; Sinks, LF; Weil, M; Pleuss, H; Hananian, J; Burgert, EO Jr; Gilchrist, GS; Necheles, T; Harris, M; Kung, F; Patterson, RB; Maurer, H; Leventhal, B; Chevalier, L; Forman, E; Holland, JF. Comparison of intermediate-dose methotrexate with cranial irradiation for the post-induction treatment of acute lymphocytic leukemia in children. N. Engl. J. Med., 1983, 308(9), 477-484.
5. Masson, E; Relling, MV; Synold, TW; Liu, Q; Schuetz, JD; Sand-lund, JT; Pui, CH; Evans, WE. Accumulation of methotrexate po-lyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J. Clin. Invest., 1996, 97(1), 73-80.
6. Calvert, H. An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents. Semin. Oncol., 1999, 26:3-10.
7. Estlin, EJ. Continuing therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of methotrexate, 6-mercaptopurine and 6-thioguanine. Cancer Treat. Rev., 2001, 27(6), 351-363.
8. van, Ede AE; Laan, RF; Blom, HJ; De Abreu, RA; van de Putte, LB. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin. Arthritis Rheum., 1998, 27(5), 277-292.
9. Longo-Sorbello, GS; Bertino, JR. Current understanding of methotrexate pharmacology and efficacy in acute leukemias. Use of newer antifolates in clinical trials. Haematologica, 2001, 86(2), 121-127.
10. Balis, FM; Holcenberg, JS; Zimm, S; Tubergen, D; Collins, JM; Murphy, RF; Gilchrist, GS; Hammond, D; Poplack, DG. The effect of methotrexate on the bioavailability of oral 6-mercaptopurine. Clin. Pharmacol. Ther., 1987, 41(4):384-387.
11. Bökkerink, JP; Bakker, MA; Hulscher, TW; De Abreu, RR; Schret-len, ED; van Laarhoven, JP; De Bruyn, CH. Sequence-, time-and dose-dependent synergism of methotrexate and 6-mercaptopurine in malignant human T-lymphoblasts. Biochem. Pharmacol., 1986, 35(20), 3549-3555.
12. Dervieux, T; Hancock, M; Evans, W; Pui, C-H; Relling, MV. Effect of methotrexate polyglutamates on thioguanine nucleotide concentrations during continuation therapy of acute lymphoblastic leukemia with mercaptopurine. Leukemia, 2002, 16(2), 209-212.
13. Goldman, ID; Lichtenstein, NS; Oliverio, VT. Carrier-mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cell. J. Biol. Chem., 1968, 243(19), 5007-5017.
14. Matherly, LH; Hou, Z; Deng, Y. Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. Cancer Metastasis Rev., 2007, 26(1), 111-128.
15. Whetstine, JR; Flatley, RM; Matherly, LH. The human reduced folate carrier gene is ubiquitously and differentially expressed in normal human tissues: identification of seven non-coding exons and characterization of a novel promoter. Biochem. J., 2002, 367, 629-640.
16. Spinella, MJ; Brigle, KE; Sierra, EE; Goldman, ID. Distinguishing between folate receptor-alpha-mediated transport and reduced fo-late carrier-mediated transport in L1210 leukemia cells. J. Biol. Chem., 1995, 270(14), 7842-7849.
17. Goldman, ID; Matherly, LH. The cellular pharmacology of methotrexate. Pharmacol. Ther., 1985, 28(1), 77-102.
18. Olsen, EA. The pharmacology of methotrexate. J. Am. Acad. Der-matol., 1991, 25, 306-318.
19. Warren, RD; Nichols, AP; Bender, RA. Membrane transport of methotrexate in human lymphoblastoid cells. Cancer Res., 1978, 38(3), 668-671.
20. Baugh, CM; Krumdieck, CL; Nair, MG. Polygammaglutamyl metabolites of methotrexate. Biochem. Biophys. Res. Commun., 1973, 52(1), 27-34.
21. Moran, RG; Werkheiser, WC; Zakrzewski, SF. Folate metabolism in mammalian cells in culture. I Partial characterization of the fo-late derivatives present in L1210 mouse leukemia cells. J. Biol. Chem., 1976, 251(12), 3569-3575.
22. Moran, RG. Roles of folylpoly-gamma-glutamate synthetase in therapeutics with tetrahydrofolate antimetabolites: an overview. Semin. Oncol., 1999, 26, 24-32.
23. McGuire, JJ; Bertino, JR. Enzymatic synthesis and function of folylpolyglutamates. Mol. Cell. Biochem., 1981, 38, 19-48.
24. McGuire, JJ; Russell, CA; Balinska, M. Human cytosolic and mi-tochondrial folylpolyglutamate synthetase are electrophoretically distinct. Expression in antifolate-sensitive and-resistant human cell lines. J. Biol. Chem., 2000, 275(17), 13012-13016.
25. Genestier, L; Paillot, R; Quemeneur, L; Izeradjene, K; Revillard, JP. Mechanisms of action of methotrexate. Immunopharmacology., 2000, 47(2-3), 247-257.
26. Allegra, CJ; Drake, JC; Jolivet, J; Chabner, BA. Inhibition of phos-phoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc. Natl. Acad. Sci. U.S.A., 1985, 82(15), 4881-4885.
27. Chabner, BA; Allegra, CJ; Curt, GA; Clendeninn, NJ; Baram, J; Koizumi, S; Drake, JC; Jolivet, J. Polyglutamation of methotrexate. Is methotrexate a prodrug? J. Clin. Invest., 1985, 76(3), 907-912.
28. Dervieux, T; Greenstein, N; Kremer, J. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum., 2006, 54(10), 3095-3103.
29. Ranganathan, P; McLeod, HL. Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum., 2006, 54(5), 1366-1377.
30. Schirch, V; Strong, WB. Interaction of folylpolyglutamates with enzymes in one-carbon metabolism. Arch. Biochem. Biophys, 1989, 269(2), 371-380.
31. Matherly, LH; Goldman, DI. Membrane transport of folates. Vitam. Horm., 2003, 66, 403-456.
32. Volk, EL; Schneider, E. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res., 2003, 63(17), 5538-5543.
33. Wielinga, P; Hooijberg, JH; Gunnarsdottir, S; Kathmann, I; Reid, G; Zelcer, N; van der Born, K; de Haas, M; van der Heijden, I; Kaspers, G; Wijnholds, J; Jansen, G; Peters, G; Borst, P. The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res., 2005, 65(10), 4425-4430.
34. Zeng, H; Chen, ZS; Belinsky, MG; Rea, PA; Kruh, GD. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res., 2001, 61(19), 7225-7232.
35. Gorlick, R; Goker, E; Trippett, T; Waltham, M; Banerjee, D; Ber-tino, JR. Intrinsic and acquired resistance to methotrexate in acute leukemia. N. Engl. J. Med., 1996, 335(14), 1041-1048.
36. Jolivet, J; Cowan, KH; Curt, GA; Clendeninn, NJ; Chabner, BA. The pharmacology and clinical use of methotrexate. N. Engl. J. Med., 1983, 309(18), 1094-1104.
37. French, D; Yang, W; Cheng, C; Raimondi, SC; Mullighan, CG; Downing, JR; Evans, WE; Pui, CH; Relling, MV. Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia. Blood, 2009, 113(19), 4512-4520.
38. Galpin, AJ; Schuetz, JD; Masson, E; Yanishevski, Y; Synold, TW; Barredo, JC; Pui, CH; Relling, MV; Evans, WE. Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamyla-tion and cytotoxicity. Mol. Pharmacol., 1997, 52(1), 155-163.
39. Kager, L; Cheok, M; Yang, W; Zaza, G; Cheng, Q; Panetta, JC; Pui, CH; Downing, JR; Relling, MV; Evans, WE. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J. Clin. Invest., 2005, 115(1), 110-117.
40. Synold, TW; Relling, MV; Boyett, JM; Rivera, GK; Sandlund, JT; Mahmoud, H; Crist, WM; Pui, CH; Evans, WE. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J. Clin. Invest., 1994, 94(5), 1996-2001.
41. Barredo, JC; Synold, TW; Laver, J; Relling, MV; Pui, CH; Priest, DG; Evans, WE. Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. Blood., 1994, 84(2), 564-569.
42. Panetta, JC; Yanishevski, Y; Pui, C-H; Sandlund, JT; Rubnitz, J; Rivera, GK; Ribeiro, R; Evans, WE; Relling, MV. A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia. Cancer Chemother. Pharmacol., 2002, 50(5), 419-428.
43. Rots, MG; Pieters, R; Peters, GJ; van Zantwijk, CH; Mauritz, R; Noordhuis, P; Willey, JC; Hählen, K; Creutzig, U; Janka-Schaub, G; Kaspers, GJ; Veerman, AJ; Jansen, G. Circumvention of methotrexate resistance in childhood leukemia subtypes by rationally designed antifolates. Blood., 1999, 94(9), 3121-3128.
44. Barrueco, JR; O'Leary, DF; Sirotnak, FM. Metabolic turnover of methotrexate polyglutamates in lysosomes derived from S180 cells. Definition of a two-step process limited by mediated lysosomal permeation of polyglutamates and activating reduced sulfhydryl compounds. J. Biol. Chem., 1992, 267(22), 15356-15361.
45. Panetta, JC; Wall, A; Pui, C-H; Relling, MV; Evans, WE. Methotrexate intracellular disposition in acute lymphoblastic leu-kemia: a mathematical model of gamma-glutamyl hydrolase activity. Clin. Cancer Res., 2002, 8(7), 2423-2429.
46. Li, WW; Waltham, M; Tong, W; Schweitzer, BI; Bertino, JR. Increased activity of gamma-glutamyl hydrolase in human sarcoma cell lines: a novel mechanism of intrinsic resistance to methotrexate (MTX). Adv. Exp. Med. Biol., 1993, 338, 635-638.
47. Longo, GS; Gorlick, R; Tong, WP; Lin, S; Steinherz, P; Bertino, JR. gamma-Glutamyl hydrolase and folylpolyglutamate synthetase activities predict polyglutamylation of methotrexate in acute leu-kemias. Oncol. Res., 1997, 9(5), 259-263.
48. Rhee, MS; Wang, Y; Nair, MG; Galivan, J. Acquisition of resistance to antifolates caused by enhanced gamma-glutamyl hydrolase activity. Cancer Res., 1993, 53, 2227-2230.
49. Jacobs, SA; Stoller, RG; Chabner, BA; Johns, DG. 7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate. J. Clin. Invest., 1976, 57(2), 534-538.
50. Newton, PA; Blakley, RL. 7-Hydroxymethotrexate formation in a human lymphoblastic cell line. Biochem. Biophys. Res. Commun., 1984, 122(3), 1212-1217.
51. Drake, JC; Allegra, CJ; Baram, J; Kaufman, BT; Chabner, BA. Effects on dihydrofolate reductase of methotrexate metabolites and intracellular folates formed following methotrexate exposure of human breast cancer cells. Biochem. Pharmacol., 1987, 36(14), 2416-2418.
52. Farquhar, D; Loo, TL. Synthesis and biologic evaluation of 7-hydroxymethotrexate, 7-methylaminopterin, and 7-methylmethotrexate. J. Med. Chem., 1972, 15(5), 567-569.
53. Jordan, CG; Rashidi, MR; Laljee, H; Clarke, SE; Brown, JE; Beedham, C. Aldehyde oxidase-catalysed oxidation of methotrexate in the liver of guinea-pig, rabbit and man. J. Pharm. Pharmacol., 1999, 51(4), 411-418.
54. Moriyasu, A; Sugihara, K; Nakatani, K; Ohta, S; Kitamura, S. In vivo-in vitro relationship of methotrexate 7-hydroxylation by aldehyde oxidase in four different strain rats. Drug Metab. Pharma-cokinet., 2006 21(6), 485-491.
55. Sholar, PW; Baram, J; Seither, R; Allegra, CJ. Inhibition of folate-dependent enzymes by 7-OH-methotrexate. Biochem. Pharmacol., 1988, 37(18), 3531-3534.
56. Fabre, G; Matherly, LH; Favre, R; Catalin, J; Cano, JP. In vitro formation of polyglutamyl derivatives of methotrexate and 7-hydroxymethotrexate in human lymphoblastic leukemia cells. Cancer Res., 1983, 43(10), 4648-4652.
57. Fabre, G; Fabre, I; Matherly, LH; Cano, JP; Goldman, ID. Synthesis and properties of 7-hydroxymethotrexate polyglutamyl derivatives in Ehrlich ascites tumor cells in vitro. J. Biol. Chem., 1984, 259(8), 5066-5072.
58. Lankelma, J; van der Klein, E; Ramaekers, F. The role of 7-hydroxymethotrexate during methotrexate anti-cancer therapy. Cancer Lett., 1980, 9(2), 133-142.
59. Sonneveld, P; Schultz, FW; Nooter, K; Hählen, K. Pharmacokinet-ics of methotrexate and 7-hydroxy-methotrexate in plasma and bone marrow of children receiving low-dose oral methotrexate. Cancer Chemother. Pharmacol., 1986, 18(2), 111-116.
60. Dhondt, JL; Hayte, JM; Millot, F; Klein, R; Blais, JC; Pfleiderer, W. 2, 4-diamino-7-hydroxy-pteridines, a new class of catabolites of methotrexate. Eur. J. Biochem., 1991, 200(1), 237-244.
61. Donehower, RC; Hande, KR; Drake, JC; Chabner, BA. Presence of 2, 4-diamino-N10-methylpteroic acid after high-dose methotrexate. Clin. Pharmacol. Ther., 1979, 26(1), 63-72.
62. Borst, P; Evers, R; Kool, M; Wijnholds, J. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst., 2000, 92(16), 1295-1302.
63. Dean, M; Allikmets, R. Complete characterization of the human ABC gene family. J. Bioenerg. Biomembr., 2001, 33(6), 475-479.
64. Plasschaert, SLA; de Bont, ESJM; Boezen, M; vander Kolk, DM; Daenen, SMJG; Faber, KN; Kamps, WA; de Vries, EG; Vellenga, E. Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. Clin. Cancer Res., 2005, 11, 8661-8668.
65. Vlaming, MLH; Pala, Z; van Esch, A; Wagenaar, E; van Tellingen, O; de Waart, DR; Oude Elferink, RP; van de Wetering, K; Schinkel, AH. Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate. Clin. Cancer Res., 2008, 14(24), 8152-8160.
66. Adachi, M; Reid, G; Schuetz, JD. Therapeutic and biological importance of getting nucleotides out of cells: a case for the ABC transporters, MRP4 and 5. Adv. Drug Deliv. Rev., 2002, 54(10), 1333-1342.
67. Albermann, N; Schmitz-Winnenthal, FH; Z'graggen, K; Volk, C; Hoffmann, MM; Haefeli, WE; Weiss, J. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem. Pharmacol., 2005, 70(6), 949-958.
68. Assaraf, YG; Rothem, L; Hooijberg, JH; Stark, M; Ifergan, I; Kathmann, I; Weiss, J. Loss of multidrug resistance protein 1 expression and folate efflux activity results in a highly concentrative folate transport in human leukemia cells. J. Biol. Chem., 2003, 278(9), 6680-6686.
69. Assaraf, YG. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist. Updat., 2006, 9(4-5), 227-246.
70. Flens, MJ; Zaman, GJ; van der Valk, P; Izquierdo, MA; Schroei-jers, AB; Scheffer, GL; van der Groep, P; de Haas, M; Meijer, CJ; Scheper, RJ.Tissue distribution of the multidrug resistance protein. Am. J. Pathol., 1996, 148(4), 1237-1247.
71. Hooijberg, JH; Broxterman, HJ; Kool, M; Assaraf, YG; Peters, GJ; Noordhuis, P; Scheper, RJ; Borst, P; Pinedo, HM; Jansen, G. Anti-folate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res., 1999, 59(11), 2532-2535.
72. Zeng, H; Bain, LJ; Belinsky, MG; Kruh, GD. Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. Cancer Res., 1999, 59(23), 5964-5967.
73. Sczesny, F; Hempel, G; Boos, J; Blaschke, G. Capillary electropho-retic drug monitoring of methotrexate and leucovorin and their metabolites. J. Chromatogr. B Biomed. Sci. Appl., 1998, 718(1), 177-185.
74. Belinsky, MG; Chen, Z-S; Shchaveleva, I; Zeng, H; Kruh, GD. Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res., 2002, 62(21), 6172-6177.
75. Chen, Z-S; Hopper-Borge, E; Belinsky, MG; Shchaveleva, I; Koto-va, E; Kruh, GD. Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol. Pharmacol., 2003, 63(2), 351-358.
76. Guo, Y; Kotova, E; Chen, Z-S; Lee, K; Hopper-Borge, E; Belinsky, MG; Kruh, GD. MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropy-rimidines 2', 3'-dideoxycytidine and 9'-(2'-phosphonylmethoxy-ethyl)adenine. J. Biol. Chem., 2003, 278(32), 29509-29514.
77. Hopper-Borge, E; Chen, Z-S; Shchaveleva, I; Belinsky, MG; Kruh, GD. Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res., 2004, 64(14), 4927-4930.
78. Chen, Z-S; Lee, K; Walther, S; Raftogianis, RB; Kuwano, M; Zeng, H; Kruh, GD. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res., 2002, 62(11), 3144-3150.
79. Spinella, MJ; Brigle, KE; Freemantle, SJ; Sierra, EE; Goldman, ID. Comparison of methotrexate polyglutamylation in L1210 leukemia cells when influx is mediated by the reduced folate carrier or the folate receptor. Lack of evidence for influx route-specific effects. Biochem. Pharmacol., 1996, 52(5), 703-712.
80. Maliepaard, M; Scheffer, GL; Faneyte, IF; van Gastelen, MA; Pijnenborg, AC; Schinkel, AH; van De Vijver, MJ; Scheper, RJ; Schellens, JH. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res., 2001, 61(8), 3458-3464.
81. Zhou, S; Schuetz, JD; Bunting, KD; Colapietro, AM; Sampath, J; Morris, JJ; Lagutina, I; Grosveld, GC; Osawa, M; Nakauchi, H; Sorrentino, BP. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat. Med., 2001, 7(9), 1028-1034.
82. Chen, Z-S; Robey, RW; Belinsky, MG; Shchaveleva, I; Ren, X-Q; Sugimoto, Y; Ross, DD; Bates, SE; Kruh, GD. Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res., 2003, 63(14), 4048-4054.
83. Volk, EL; Rohde, K; Rhee, M; McGuire, JJ; Doyle, LA; Ross, DD; Schneider, E. Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux. Cancer Res., 2000, 60(13), 3514-3521.
84. Volk, EL; Farley, KM; Wu, Y; Li, F; Robey, RW; Schneider, E. Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res., 2002, 62(17), 5035-5040.
85. Shafran, A; Ifergan, I; Bram, E; Jansen, G; Kathmann, I; Peters, GJ; Robey, RW; Bates, SE; Assaraf, YG. ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydro-philic antifolates. Cancer Res., 2005, 65(18), 8414-8422.
86. Rhee, MS; Schneider, E. Lack of an effect of breast cancer resistance protein (BCRP/ABCG2) overexpression on methotrexate po-lyglutamate export and folate accumulation in a human breast cancer cell line. Biochem. Pharmacol., 2005, 69(1), 123-132.
87. Chaudhary, PM; Roninson, IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell., 1991, 66(1), 85-94.
88. Chaudhary, PM; Mechetner, EB; Roninson, IB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood., 1992, 80(11), 2735-2739.
89. de Graaf, D; Sharma, RC; Mechetner, EB; Schimke, RT; Roninson, IB. P-glycoprotein confers methotrexate resistance in 3T6 cells with deficient carrier-mediated methotrexate uptake. Proc. Natl. Acad. Sci. U.S.A., 1996, 93(3), 1238-1242.
90. Gifford, AJ; Kavallaris, M; Madafiglio, J; Matherly, LH; Stewart, BW; Haber, M; Norris, MD. P-glycoprotein-mediated methotrexate resistance in CCRF-CEM sublines deficient in methotrexate accumulation due to a point mutation in the reduced folate carrier gene. Int. J. Cancer., 1998, 78(2), 176-181.
91. Assaraf, YG; Goldman, ID. Loss of folic acid exporter function with markedly augmented folate accumulation in lipophilic antifo-late-resistant mammalian cells. J. Biol. Chem., 1997, 272(28), 17460-17466.
92. Hooijberg, JH; de Vries, NA; Kaspers, GJL; Pieters, R; Jansen, G; Peters, GJ. Multidrug resistance proteins and folate supplementation: therapeutic implications for antifolates and other classes of drugs in cancer treatment. Cancer Chemother. Pharmacol., 2006, 58(1), 1-12.
93. Bostrom, B; Erdmann, G. Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol., 1993, 15(1), 80-86.
94. Elion, GB. The purine path to chemotherapy. Science., 1989, 244(4900), 41-47.
95. Lewis, AS; Murphy, L; McCalla, C; Fleary, M; Purcell, S. Inhibition of mammalian xanthine oxidase by folate compounds and amethopterin. J. Biol. Chem., 1984, 259(1), 12-15.
96. Innocenti, F; Danesi, R; Di Paolo, A; Loru, B; Favre, C; Nardi, M; Bocci, G; Nardini, D; Macchia, P; Del Tacca, M. Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate. Cancer Chemother. Pharmacol., 1996, 37(5), 409-414.
97. Bökkerink, JP; Damen, FJ; Hulscher, MW; Bakker, MA; De Abreu, RA. Biochemical evidence for synergistic combination treatment with methotrexate and 6-mercaptopurine in acute lym-phoblastic leukemia. Haematol Blood Transfus., 1990, 33, 110-117.
98. Giverhaug, T; Loennechen, T; Aarbakke, J. The interaction of 6-mercaptopurine (6-MP) and methotrexate (MTX). Gen. Pharmacol., 1999, 33(4), 341-346.
99. Fiskerstrand, T; Ueland, PM; Refsum, H. Folate depletion induced by methotrexate affects methionine synthase activity and its susceptibility to inactivation by nitrous oxide. J. Pharmacol. Exp. Ther., 1997, 282(3), 1305-1311.
100. Nesher, G; Moore, TL; Dorner, RW. In vitro effects of methotrexate on peripheral blood monocytes: modulation by folinic acid and S-adenosylmethionine. Ann. Rheum. Dis., 1991, 50(9), 637-641.
101. Giverhaug, T; Loennechen, T; Aarbakke, J. Increased concentrations of methylated 6-mercaptopurine metabolites and 6-thioguanine nucleotides in human leukemic cells in vitro by methotrexate. Biochem. Pharmacol., 1998, 55(10), 1641-1646.
102. Dervieux, T; Hancock, ML; Pui, C-H; Rivera, GK; Sandlund, JT; Ribeiro, RC; Boyett, J; Evans, WE; Relling, MV. Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia. Clin. Pharmacol. Ther., 2003, 73(6), 506-516.
103. Zaza, G; Cheok, M; Yang, W; Panetta, JC; Pui, C-H; Relling, MV; Evans, WE. Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. Blood., 2005, 106(5), 1778-1785.
104. Adam de Beaumais, T; Fakhoury, M; Medard, Y; Azougagh, S; Zhang, D; Yakouben, K; Jacqz-Aigrain, E. Determinants of mer-captopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy. Br J Clin Pharmacol., 2011, 71(4), 575-584.
105. Chen, ZS; Lee, K; Kruh, GD. Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J. Biol. Chem., 2001, 276(36), 33747-33754.
106. Janke, D; Mehralivand, S; Strand, D; Gödtel-Armbrust, U; Habermeier, A; Gradhand, U; Fischer, C; Toliat, MR; Fritz, P; Zanger, UM; Schwab, M; Fromm, MF; Nürnberg, P; Wojnowski, L; Closs, EI; Lang T. 6-mercaptopurine and 9-(2-phosphonyl-methoxyethyl) adenine (PMEA) transport altered by two missense mutations in the drug transporter gene ABCC4. Hum. Mutat., 2008, 29(5), 659-669.
107. Lai, L; Tan, TMC. Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues. Biochem. J., 2002, 361, 497-503.
108. Russel, FGM; Koenderink, JB; Masereeuw, R. Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules. Trends Pharmacol. Sci., 2008, 29(4), 200-207.
109. Van Aubel, RAMH; Smeets, PHE; van den Heuvel, JJMW; Russel, FGM. Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am. J. Physiol. Renal Physiol., 2005, 288(2), F327-333.
110. Wijnholds, J; Mol, CA; van Deemter, L; de Haas, M; Scheffer, GL; Baas, F; Beijnen, JH; Scheper, RJ; Hatse, S; De Clercq, E; Balzarini, J; Borst, P. Multidrug-resistance protein 5 is a multis-pecific organic anion transporter able to transport nucleotide analogs. Proc. Natl. Acad. Sci. U.S.A., 2000, 97(13), 7476-7481.
111. Zaza, G; Cheok, M; Krynetskaia, N; Thorn, C; Stocco, G; Hebert, JM; McLeod, H; Weinshilboum, RM; Relling, MV; Evans, WE; Klein, TE; Altman, RB. Thiopurine pathway. Pharmacogenet. Ge-nomics., 2010, 20(9), 573-574.
112. Ge, Y; Haska, CL; LaFiura, K; Devidas, M; Linda, SB; Liu, M; Thomas, R; Taub, JW; Matherly, LH. Prognostic role of the reduced folate carrier, the major membrane transporter for methotrexate, in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Clin. Cancer Res., 2007, 13, 451-457.
113. Gorlick, R; Goker, E; Trippett, T; Steinherz, P; Elisseyeff, Y; Ma-zumdar, M; Flintoff, WF; Bertino, JR. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced fo-late carrier expression. Blood., 1997, 89(3), 1013-1018.
114. Levy, AS; Sather, HN; Steinherz, PG; Sowers, R; La, M; Moscow, JA; Gaynon, PS; Uckun, FM; Bertino, JR; Gorlick, R; Children's Cancer Group Study. Reduced folate carrier and dihydrofolate re-ductase expression in acute lymphocytic leukemia may predict outcome: a Children's Cancer Group Study. J. Pediatr. Hematol. Oncol., 2003, 25(9), 688-695.
115. Zhang, L; Wong, SC; Matherly, LH. Structure and organization of the human reduced folate carrier gene. Biochim. Biophys. Acta., 1998, 1442, 389-393.
116. Pui, CH; Evans, WE. Acute lymphoblastic leukemia. N. Engl. J. Med., 1998, 339(9), 605-615.
117. Belkov, VM; Krynetski, EY; Schuetz, JD; Yanishevski, Y; Mas-son, E; Mathew, S; Raimondi, S; Pui, CH; Relling, MV; Evans, WE. Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation. Blood., 1999, 93(5), 1643-1650.
118. Moscow, JA; Gong, M; He, R; Sgagias, MK; Dixon, KH; Anzick, SL; Meltzer, PS; Cowan, KH. Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells. Cancer Res., 1995, 55(17), 3790-3794.
119. Raimondi, SC; Pui, CH; Hancock, ML; Behm, FG; Filatov, L; Rivera, GK. Heterogeneity of hyperdiploid (51-67) childhood acute lymphoblastic leukemia. Leukemia, 1996, 10(2), 213-224.
120. Gregers, J; Christensen, IJ; Dalhoff, K; Lausen, B; Schroeder, H; Rosthoej, S; Carlsen, N; Schmiegelow, K; Peterson, C. The association of reduced folate carrier 80G>A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number. Blood., 2010, 115(23), 4671-4677.
121. Whitehead, VM; Vuchich, MJ; Lauer, SJ; Mahoney, D; Carroll, AJ; Shuster, JJ; Esseltine, DW; Payment, C; Look, AT; Akabutu, J. Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (greater than 50 chromosomes) B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood., 1992, 80(5), 1316-1323.
122. Kaufman, Y; Drori, S; Cole, PD; Kamen, BA; Sirota, J; Ifergan, I; Arush, MW; Elhasid, R; Sahar, D; Kaspers, GJ; Jansen, G; Matherly, LH; Rechavi, G; Toren, A; Assaraf, YG. Reduced folate carrier mutations are not the mechanism underlying methotrexate resistance in childhood acute lymphoblastic leukemia. Cancer., 2004, 100(4), 773-782.
123. Whetstine, JR; Gifford, AJ; Witt, T; Liu, XY; Flatley, RM; Norris, M; Haber, M; Taub, JW; Ravindranath, Y; Matherly, LH. Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high-frequency G/A variant at position 80 and transport properties of the His(27) and Arg(27) carriers. Clin. Cancer Res., 2001, 7(11), 3416-3422.
124. Leil, TA; Endo, C; Adjei, AA; Dy, GK; Salavaggione, OE; Reid, JR; Ames, MM; Adjei, AA. Identification and characterization of genetic variation in the folylpolyglutamate synthase gene. Cancer Res., 2007, 67(18), 8772-8782.
125. Cheng, Q; Wu, B; Kager, L; Panetta, JC; Zheng, J; Pui, C-H; Relling, MV; Evans, WE. A substrate specific functional polymorphism of human gamma-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblas-tic leukaemia cells. Pharmacogenetics., 2004, 14(8), 557-567.
126. Chave, KJ; Ryan, TJ; Chmura, SE; Galivan, J. Identification of single nucleotide polymorphisms in the human gamma-glutamyl hydrolase gene and characterization of promoter polymorphisms. Gene., 2003, 319, 167-175.
127. Beck, J; Handgretinger, R; Dopfer, R; Klingebiel, T; Niethammer, D; Gekeler, V. Expression of mdr1, mrp, topoisomerase II alpha/beta, and cyclin A in primary or relapsed states of acute lym-phoblastic leukaemias. Br. J. Haematol., 1995, 89(2), 356-363.
128. Cascorbi, I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol. Ther., 2006, 112(2), 457-473.
129. Conrad, S; Kauffmann, HM; Ito, K; Deeley, RG; Cole, SP; Schrenk, D. Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution. J. Hum. Genet., 2001, 46(11), 656-663.
130. Conrad, S; Kauffmann, H-M; Ito, K; Leslie, EM; Deeley, RG; Schrenk, D; Cole, SP. A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance. Pharmacogenetics., 2002, 12(4), 321-330.
131. Plasschaert, SLA; Vellenga, E; de Bont, ESJM; van der Kolk, DM; Veerman, AJP; Sluiter, WJ; Daenen, SM; de Vries, EG; Kamps, WA. High functional P-glycoprotein activity is more often present in T-cell acute lymphoblastic leukaemic cells in adults than in children. Leuk. Lymphoma., 2003, 44(1), 85-95.
132. Sauerbrey, A; Voigt, A; Wittig, S; Häfer, R; Zintl, F. Messenger RNA analysis of the multidrug resistance related protein (MRP1) and the lung resistance protein (LRP) in de novo and relapsed childhood acute lymphoblastic leukemia. Leuk. Lymphoma., 2002, 43(4), 875-879.
133. Swerts, K; De Moerloose, B; Dhooge, C; Laureys, G; Benoit, Y; Philippé, J. Prognostic significance of multidrug resistance-related proteins in childhood acute lymphoblastic leukaemia. Eur. J. Cancer., 2006, 42(3), 295-309.
134. Colombo, S; Soranzo, N; Rotger, M; Sprenger, R; Bleiber, G; Furrer, H; Buclin, T; Goldstein, D; Décosterd, L; Telenti, A; Swiss HIV Cohort Study. Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo. Pharmacogenet. Genomics., 2005, 15(9), 599-608.
135. Ito, S; Ieiri, I; Tanabe, M; Suzuki, A; Higuchi, S; Otsubo, K. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics., 2001, 11(2), 175-184.
136. Meyer zu Schwabedissen, HE; Jedlitschky, G; Gratz, M; Haenisch, S; Linnemann, K; Fusch, C; Cascorbi, I; Kroemer, HK. Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation. Drug Metab. Dispos., 2005, 33(7), 896-904.
137. Rau, T; Erney, B; Göres, R; Eschenhagen, T; Beck, J; Langer, T. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Clin. Pharmacol. Ther. 2006, 80(5), 468-476.
138. Sai, K; Saito, Y; Itoda, M; Fukushima-Uesaka, H; Nishimaki-Mogami, T; Ozawa, S; Maekawa, K; Kurose, K; Kaniwa, N; Kawamoto, M; Kamatani, N; Shirao, K; Hamaguchi, T; Yamamoto, N; Kunitoh, H; Ohe, Y; Yamada, Y; Tamura, T; Yoshida, T; Minami, H; Matsumura, Y; Ohtsu, A; Saijo, N; Sawada, J. Genetic variations and haplotypes of ABCC2 encoding MRP2 in a Japanese population. Drug Metab. Pharmacokinet. 2008, 23(2), 139-147.
139. Steinbach, D; Wittig, S; Cario, G; Viehmann, S; Mueller, A; Gruhn, B; Haefer, R; Zintl, F; Sauerbrey, A. The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male patients and T-cell immunophenotype. Blood., 2003 102(13), 4493-4498.
140. Lang, T; Hitzl, M; Burk, O; Mornhinweg, E; Keil, A; Kerb, R; Klein, K; Zanger, UM; Eichelbaum, M; Fromm, MF. Genetic polymorphisms in the multidrug resistance-associated protein 3 (ABCC3, MRP3) gene and relationship to its mRNA and protein expression in human liver. Pharmacogenetics., 2004, 14(3), 155-164.
141. Sampath, J; Adachi, M; Hatse, S; Naesens, L; Balzarini, J; Flatley, RM; Matherly, LH; Schuetz, JD. Role of MRP4 and MRP5 in biology and chemotherapy. AAPS PharmSci., 2002, 4(3), E14.
142. Ansari, M; Sauty, G; Labuda, M; Gagné, V; Laverdière, C; Moghrabi, A; Sinnett, D; Krajinovic, M. Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood., 2009, 114(7), 1383-1386.
143. Krishnamurthy, P; Schwab, M; Takenaka, K; Nachagari, D; Morgan, J; Leslie, M; Du, W; Boyd, K; Cheok, M; Nakauchi, H; Marzolini, C; Kim, RB; Poonkuzhali, B; Schuetz, E; Evans, W; Relling, M; Schuetz, JD. Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. Cancer Res., 2008, 68(13), 4983-4989.
144. Gwee, PC; Tang, K; Sew, PH; Lee, EJD; Chong, SS; Lee, CGL. Strong linkage disequilibrium at the nucleotide analogue transporter ABCC5 gene locus. Pharmacogenet. Genomics., 2005, 15(2), 91-104.
145. Ross, DD; Karp, JE; Chen, TT; Doyle, LA. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood., 2000, 96(1), 365-368.
146. Steinbach, D; Sell, W; Voigt, A; Hermann, J; Zintl, F; Sauerbrey, A. BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia., 2002, 16(8), 1443-1447.
147. Suvannasankha, A; Minderman, H; O'Loughlin, KL; Nakanishi, T; Ford, LA; Greco, WR; Wetzler, M; Ross, DD; Baer, MR. Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correla-tion with shorter disease-free survival. Br. J. Haematol., 2004, 127(4), 392-398.
148. Mitomo, H; Kato, R; Ito, A; Kasamatsu, S; Ikegami, Y; Kii, I; Kudo, A; Kobatake, E; Sumino, Y; Ishikawa, T. A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport. Biochem. J. 2003, 373, 767-774.
149. Nakanishi, T; Karp, JE; Tan, M; Doyle, LA; Peters, T; Yang, W; Wei, D; Ross, DD. Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients. Clin. Cancer Res., 2003, 9(9), 3320-3328.
150. Bäckström, G; Taipalensuu, J; Melhus, H; Brändström, H; Svens-son, A-C; Artursson, P; Kindmark A. Genetic variation in the ATP-binding cassette transporter gene ABCG2 (BCRP) in a Swedish population. Eur J Pharm Sci., 2003, 18(5), 359-364.
151. de Jong, FA; Marsh, S; Mathijssen, RHJ; King, C; Verweij, J; Sparreboom, A; McLeod, HL. ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on iri-notecan disposition. Clin. Cancer Res., 2004, 10(17), 5889-5894.
152. Imai, Y; Nakane, M; Kage, K; Tsukahara, S; Ishikawa, E; Tsuruo, T; Miki, Y; Sugimoto, Y. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol. Cancer Ther., 2002, 1(8), 611-616.
153. Kobayashi, D; Ieiri, I; Hirota, T; Takane, H; Maegawa, S; Kigawa, J; Suzuki, H; Nanba, E; Oshimura, M; Terakawa N, Otsubo K, Mine K, Sugiyama Y. Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab. Dispos. 2005, 33(1), 94-101.
154. Mizuarai, S; Aozasa, N; Kotani, H. Single nucleotide polymorphisms result in impaired membrane localization and reduced at-pase activity in multidrug transporter ABCG2. Int. J. Cancer., 2004, 109(2), 238-246.
155. Zamber, CP; Lamba, JK; Yasuda, K; Farnum, J; Thummel, K; Schuetz, JD; Schuetz, EG. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics., 2003, 13(1), 19-28.
156. Matherly, LH. Molecular and cellular biology of the human reduced folate carrier. Prog. Nucleic Acid Res. Mol. Biol. 2001, 67, 131-162.
157. Zhao, R; Goldman, ID. Resistance to antifolates. Oncogene. 2003, 22(47): 7431-7457.
158. Schmiegelow, K; Schrøder, H; Gustafsson, G; Kristinsson, J; Glomstein, A; Salmi, T; Wranne, L. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology. J. Clin. Oncol., 1995, 13(2), 345-351.
159. Dervieux, T; Brenner, TL; Hon, YY; Zhou, Y; Hancock, ML; Sandlund, JT; Rivera, GK; Ribeiro, RC; Boyett, JM; Pui, CH; Relling, MV; Evans, WE. De novo purine synthesis inhibition and an-tileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. Blood, 2002, 100(4), 1240-1247.
160. Schipper, RG; van den Heuvel, LP; Verhofstad, AAJ; De Abreu, RA. Polyamines and DNA methylation in childhood leukaemia. Biochem. Soc. Trans., 2007, 35, 331-335.
161. Nygaard, U; Schmiegelow, K. Dose reduction of coadministered 6-mercaptopurine decreases myelotoxicity following high-dose methotrexate in childhood leukemia. Leukemia. 2003, 17(7), 1344-1348.
162. Wessels, JAM; Huizinga, TWJ; Guchelaar, H-J. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford)., 2008, 47(3), 249-255.
163. Dervieux, T; Furst, D; Lein, DO; Capps, R; Smith, K; Walsh, M; Kremer, J. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum. 2004, 50(9), 2766-2774.
164. van der Straaten, RJHM; Wessels, JAM; de Vries-Bouwstra, JK; Goekoop-Ruiterman, YPM; Allaart, CF; Bogaartz, J; Tiller, M; Huizinga, TW; Guchelaar, HJ. Exploratory analysis of four poly-morphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients. Pharmacoge-nomics. 2007, 8(2), 141-150.
165. Nersting, J; Schmiegelow, K. Pharmacogenomics of methotrexate: moving towards individualized therapy. Pharmacogenomics. 2009, 10(12), 1887-1889.
166. Leclerc, GJ; Mou, C; Leclerc, GM; Mian, AM; Barredo, JC. His-tone deacetylase inhibitors induce FPGS mRNA expression and in-tracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia: implications for combination therapy. Leukemia., 2010, 24(3), 552-562.
167. Stark, M; Wichman, C; Avivi, I; Assaraf, YG. Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of antifolate resistance in leukemia. Blood., 2009, 113(18), 4362-4369.
168. Cheng, Q; Cheng, C; Crews, KR; Ribeiro, RC; Pui, C-H; Relling, MV; Evans, WE. Epigenetic regulation of human gamma-glutamyl hydrolase activity in acute lymphoblastic leukemia cells. Am. J. Hum. Genet. 2006, 79(2), 264-274.
169. Kearns, GL; Abdel-Rahman, SM; Alander, SW; Blowey, DL; Leeder, JS; Kauffman, RE. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 2003;349(12):1157-1167.
170. Leeder, JS; Kearns, GL; Spielberg, SP; van den Anker, J. Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science. J Clin Pharmacol. 2010;50(12):1377-1387.
171. Bakos, E; Evers, R; Calenda, G; Tusnády, GE; Szakács, G; Váradi, A; Sarkadi, B. Characterization of the amino-terminal regions in the human multidrug resistance protein (MRP1). J. Cell. Sci., 2000, 113, 4451-4461.
172. Zeng, H; Liu, G; Rea, PA; Kruh, GD. Transport of amphipathic anions by human multidrug resistance protein 3. Cancer Res., 2000, 60(17), 4779-4784.
173. van Aubel, RAMH; Smeets, PHE; Peters, JGP; Bindels, RJM; Russel, FGM. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J. Am. Soc. Nephrol., 2002, 13(3), 595-603.
174. Pratt, S; Chen, V; Perry, WI 3rd; Starling, JJ; Dantzig, AH. Kinetic validation of the use of carboxydichlorofluorescein as a drug surrogate for MRP5-mediated transport. Eur J Pharm Sci., 2006, 27(5), 524-532.
175. Chango, A; Emery-Fillon, N; de Courcy, GP; Lambert, D; Pfister, M; Rosenblatt, DS; Nicolas, JP. A polymorphism (80G→A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol. Genet. Metab., 2000, 70(4), 310-315.
176. de Jonge, R; Hooijberg, JH; van Zelst, BD; Jansen, G; Jansen, G; van Zantwijk, CH; Peters, GJ; Ravindranath, Y; Pieters, R; Linde-mans, J. Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia. Blood., 2005, 106(2), 717-720.
177. Laverdière, C; Chiasson, S; Costea, I; Moghrabi, A; Krajinovic, M. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood., 2002, 100(10), 3832-3834.
178. Imanishi, H; Okamura, N; Yagi, M; Noro, Y; Moriya, Y; Naka-mura, T; Hayakawa, A; Takeshima, Y; Sakaeda, T; Matsuo, M; Okumura, K. Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lym-phoblastic leukemia and malignant lymphoma. J. Hum. Genet., 2007, 52(2), 166-171.
179. Pakakasama, S; Kanchanakamhaeng, K; Kajanachumpol, S; Udomsubpayakul, U; Sirachainan, N; Thithapandha, A; Hongeng, S. Genetic polymorphisms of folate metabolic enzymes and tox-icities of high dose methotrexate in children with acute lym-phoblastic leukemia. Ann. Hematol., 2007, 86(8), 609-611.
180. Shimasaki, N; Mori, T; Samejima, H; Sato, R; Shimada, H; Yahagi, N; Torii, C; Yoshihara, H; Tanigawara, Y; Takahashi, T; Kosaki, K. Effects of methylenetetrahydrofolate reductase and reduced fo-late carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J. Pediatr. Hematol. Oncol., 2006, 28(2), 64-68.
181. Garcia-Bournissen, F; Moghrabi, A; Krajinovic, M. Therapeutic responses in childhood acute lymphoblastic leukemia (ALL) and haplotypes of gamma glutamyl hydrolase (GGH) gene. Leuk. Res., 2007, 31(7), 1023-1025.
182. Haenisch, S; Zimmermann, U; Dazert, E; Wruck, CJ; Dazert, P; Siegmund, W; Kroemer, HK; Warzok, RW; Cascorbi I. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacoge-nomics J., 2007, 7(1), 56-65. d
183. Kondo, C; Suzuki, H; Itoda, M; Ozawa, S; Sawada, J; Kobayashi, D; Ieiri, I; Mine, K; Ohtsubo, K; Sugiyama, Y. Functional analysis of SNPs variants of BCRP/ABCG2. Pharm. Res., 2004, 21(10), 1895-1903.
184. Morisaki, K; Robey, RW; Ozvegy-Laczka, C; Honjo, Y; Polgar, O; Steadman, K; Sarkadi, B; Bates, SE. Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Che-mother. Pharmacol., 2005 56(2), 161-172.
185. Ni, Z; Mao, Q. ATP-binding Cassette Efflux Transporters in Human Placenta. Curr Pharm Biotechnol [Internet]. 2010 Available from: http://www.ncbi.nlm.nih.gov/pubmed/21118087
186. Erdélyi, DJ; Kámory, E; Zalka, A; Semsei, AF; Csókay, B; An-drikovics, H; Tordai, A; Borgulya, G; Magyarosy, E; Galántai, I; Fekete, G; Falus, A; Szalai, C; Kovács, GT. The role of ABCtransporter gene polymorphisms in chemotherapy induced immu-nosuppression, a retrospective study in childhood acute lym-phoblastic leukaemia. Cell. Immunol., 2006, 244(2), 121-124.
187. Hoffmeyer, S; Burk, O; von Richter, O; Arnold, HP; Brockmöller, J; Johne, A; Cascorbi, I; Gerloff, T; Roots, I; Eichelbaum, M; Brinkmann, U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U.S.A., 2000, 97(7), 3473-3478.
188. Jamroziak, K; Robak, T. Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies. Hematology. 2004, 9(2), 91-105.